For patients with HF with recovered LVEF, would it be reasonable to begin considering GLP1 RAs, finerenone for them in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?   

The results of studies such as FINE-ARTS-HF lend promise to a space for patients with HFpEF. SELECT enrolled more of a general cardiovascular risk-enhanced population. The challenge in patients with "HFimpEF" - those that have recovered EF, is that it is difficult to understand in which category the...